377 related articles for article (PubMed ID: 16671277)
41. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
42. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
Jain VV; Evans T; Peterson MW
Respir Med; 2006 Jul; 100(7):1291-3. PubMed ID: 16545951
[TBL] [Abstract][Full Text] [Related]
43. Infliximab in fistulizing Crohn's disease.
Osterman MT; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
[TBL] [Abstract][Full Text] [Related]
44. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
45. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
46. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
47. Anti-TNF treatment in Crohn's disease: toward tailored therapy?
D'Haens G
Am J Gastroenterol; 2010 May; 105(5):1140-1. PubMed ID: 20445512
[TBL] [Abstract][Full Text] [Related]
48. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.
Ahmad NM; Ahmad KM; Younus F
J Infect; 2007 Jan; 54(1):e29-32. PubMed ID: 16678268
[TBL] [Abstract][Full Text] [Related]
49. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
[No Abstract] [Full Text] [Related]
50. Re: Triantafillidis et al.--Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment.
Fefferman DS; Alsahli M; Lodhavia PJ; Shah SA; Farrell RJ
Am J Gastroenterol; 2001 Aug; 96(8):2510-1. PubMed ID: 11513207
[No Abstract] [Full Text] [Related]
51. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far?
Sorrentino D
Digestion; 2008; 77(1):38-47. PubMed ID: 18285676
[TBL] [Abstract][Full Text] [Related]
52. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
53. Infliximab-induced acne: report of a third case.
Sladden MJ; Clarke PJ; Mitchell B
Br J Dermatol; 2008 Jan; 158(1):172. PubMed ID: 17854357
[No Abstract] [Full Text] [Related]
54. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
Rampton DS
Gut; 2005 Oct; 54(10):1360-2. PubMed ID: 16113045
[No Abstract] [Full Text] [Related]
55. [What can be expected from biological therapies for Crohn's disease?].
Lemann M
Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
[No Abstract] [Full Text] [Related]
56. Mucormycosis in a Crohn's disease patient treated with infliximab.
Wall GC; Leman BI
Digestion; 2009; 80(3):182-4. PubMed ID: 19776582
[TBL] [Abstract][Full Text] [Related]
57. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
58. Biologic therapy in Crohn's disease.
Williams MD; Omran ML; Gordon GL
Mo Med; 2009; 106(5):356-60. PubMed ID: 19902717
[TBL] [Abstract][Full Text] [Related]
59. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
60. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
